Private fee-for-service (PFFS) plans are the fastest growing, and most controversial, aspect of the Medicare Advantage (MA) program. They account for approximately 18% of total enrollment, and according to MedPAC, they are receiving payments that average 19% more than payments to traditional Medicare.
Private fee-for-service (PFFS) plans are the fastest growing, and most controversial, aspect of the Medicare Advantage (MA) program. They account for approximately 18% of total enrollment, and according to MedPAC, they are receiving payments that average 19% more than payments to traditional Medicare.
Private fee-for-service (PFFS) plans were created by the Balanced Budget Act of 1997 (BBA), and then modified by the Medicare Modernization Act of 2003 (MMA). They resemble a privately-administered version of traditional fee-for-service Medicare. They're exempt from many of Medicare's requirements for HMOs and PPOs; they are not required to create provider networks. While they receive capitated payments, they pay providers on a fee-for-service basis.
In recent years, PFFS plans have grown dramatically. From December 2005 to February 2007, enrollment in HMOs and PPOs increased from 5.1 million to 6 million, a growth rate of 18%. During the same period, enrollment in PFFS plans increased from 208,990 enrollees to 1.3 million, a growth rate of 535%. Most of this growth focused on counties with rural or urban floors, where the difference between federal payments for traditional Medicare and MA is greatest.
In June, the Centers for Medicare and Medicaid Services announced that seven insurers (representing 90% of the non-group PFFS market) had voluntarily agreed to suspend marketing of PFFS plans. The suspension will be lifted for each plan only after CMS verifies that the plan has appropriate systems and management controls in place, including verification of the beneficiary's intent to enroll, and documented training of marketing agents and brokers. Legislation has been introduced in Congress that would allow state insurance commissioners to develop standardized marketing regulations for Medicare Advantage plans.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Breakthrough T1D Awards $2.8 Million for New Center of Excellence
May 1st 2025The new research center at the University of Michigan and Oregon Health & Science University intends to develop a clinical trial platform that will be used to test several heart and kidney therapies in people living with type 1 diabetes.
Read More